| |
| |
|
| Insider
Information: |
Maraganore John |
| Relationship: |
Director |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
263,534 |
|
|
Indirect Shares
|
6,153,633 |
|
|
| Direct
Value |
$35,430,768 |
|
|
|
Indirect Value
|
$14,183,372 |
|
|
| Total
Shares |
6,417,167 |
|
|
| Total
Value |
$49,614,140 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Alnylam Pharmaceuticals Inc |
ALNY |
Chief Executive Office... |
2021-12-22 |
227,663 |
2021-12-22 |
3,133 |
Premium* |
|
|
Regulus Therapeutics Inc. |
RGLS |
Director, 10% Owner |
2012-10-10 |
0 |
2012-10-10 |
6,150,500 |
Premium* |
|
|
Agios Pharmaceuticals Inc |
AGIO |
Director |
2022-05-20 |
30,028 |
|
0 |
Premium* |
|
|
Bluebird Bio, Inc. |
BLUE |
Director |
2017-09-14 |
5,843 |
2014-07-14 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
154 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ALNY |
Alnylam Pharmaceuticals I... |
CEO |
• • – |
2009-06-17 |
4 |
OE |
$0.48 |
$19,000 |
D/D |
40,000 |
40,000 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
CEO |
• • – |
2009-06-18 |
4 |
AS |
$21.37 |
$854,648 |
D/D |
(40,000) |
0 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
CEO |
• • – |
2009-06-18 |
4 |
OE |
$0.48 |
$19,000 |
D/D |
40,000 |
28,200 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
CEO |
• • – |
2010-08-17 |
4 |
OE |
$0.48 |
$23,750 |
D/D |
50,000 |
50,000 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
CEO |
• • – |
2011-02-23 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,500 |
47,500 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
CEO |
• • – |
2011-10-11 |
4 |
AB |
$6.75 |
$9,989 |
D/D |
1,480 |
48,980 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
CEO |
• • – |
2011-11-14 |
4 |
AB |
$7.08 |
$9,997 |
D/D |
1,411 |
50,391 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
CEO |
• • – |
2011-12-12 |
4 |
AB |
$7.15 |
$9,995 |
D/D |
1,397 |
51,788 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
CEO |
• • – |
2012-01-09 |
4 |
AB |
$8.81 |
$9,995 |
D/D |
1,134 |
52,922 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
CEO |
• • – |
2012-02-21 |
4 |
B |
$10.75 |
$59,996 |
D/D |
5,581 |
58,503 |
2.81 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • • |
2012-10-10 |
4 |
A |
$0.00 |
$0 |
I/I |
6,150,500 |
6,150,500 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
CEO |
• • – |
2012-12-19 |
4 |
OE |
$0.48 |
$8,843 |
D/D |
18,617 |
77,120 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2013-02-27 |
4 |
AS |
$23.47 |
$704,019 |
D/D |
(30,000) |
47,120 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2013-02-28 |
4 |
AS |
$23.50 |
$669,900 |
D/D |
(28,503) |
18,617 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2013-07-10 |
4 |
AS |
$37.11 |
$2,226,822 |
D/D |
(60,000) |
18,617 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2013-07-10 |
4 |
OE |
$0.95 |
$57,000 |
D/D |
60,000 |
78,617 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2013-07-24 |
4 |
B |
$18.00 |
$149,994 |
D/D |
8,333 |
44,333 |
2.39 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2013-08-14 |
4 |
OE |
$0.95 |
$57,000 |
D/D |
60,000 |
78,617 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2013-08-14 |
4 |
AS |
$48.77 |
$2,938,127 |
D/D |
(60,000) |
18,617 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2013-09-11 |
4 |
OE |
$0.95 |
$56,000 |
D/D |
58,947 |
77,564 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2013-09-11 |
4 |
AS |
$55.41 |
$3,271,524 |
D/D |
(58,947) |
18,617 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2013-10-10 |
4 |
OE |
$6.78 |
$85,869 |
D/D |
12,665 |
31,282 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
CEO |
• • – |
2014-02-03 |
4 |
OE |
$6.78 |
$314,124 |
D/D |
46,331 |
77,613 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
CEO |
• • – |
2014-04-14 |
4 |
OE |
$9.14 |
$524,962 |
D/D |
28,707 |
106,320 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2014-04-29 |
4 |
B |
$44.00 |
$99,000 |
D/D |
2,250 |
46,583 |
2.39 |
- |
|
154 Records found
|
|
Page 2 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
